These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 25626321)
1. [Thalidomide, cereblon and multiple myeloma]. Ogura T Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321 [TBL] [Abstract][Full Text] [Related]
2. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
4. [Cereblon - a new target of therapy in the treatment of multiple myeloma]. Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709 [TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Zhu YX; Kortuem KM; Stewart AK Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948 [TBL] [Abstract][Full Text] [Related]
6. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
7. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
8. [Development of novel cereblon modulators and their target molecules]. Ito T Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190 [TBL] [Abstract][Full Text] [Related]
9. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623 [TBL] [Abstract][Full Text] [Related]
10. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135 [TBL] [Abstract][Full Text] [Related]
11. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related]
12. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790 [TBL] [Abstract][Full Text] [Related]
13. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720 [TBL] [Abstract][Full Text] [Related]
14. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners. Tao J; Yang J; Xu G Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989 [TBL] [Abstract][Full Text] [Related]
15. The evolving tale of immunomodulatory drugs and cereblon. Holstein SA Clin Pharmacol Ther; 2014 Nov; 96(5):538-41. PubMed ID: 25144833 [TBL] [Abstract][Full Text] [Related]
16. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574 [TBL] [Abstract][Full Text] [Related]
17. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817 [TBL] [Abstract][Full Text] [Related]
18. The molecular mechanism of thalidomide analogs in hematologic malignancies. Lindner S; Krönke J J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707 [TBL] [Abstract][Full Text] [Related]
19. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026 [TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]